Table 2.

HT in patients with breast and lung cancers. Summary of articles reviewed.

Author	Article Type	Investigation	Total Participants	Survival Outcome
Breast Cancer
Datta et al., 2016 [41]	Meta-analysis	RT vs. HT + RT in local recurrent breast cancer	N = 627 (5 RCTs, 3 cohort trials)	CR improved with HT. No survival data reported.
Loboda et al., 2020 [43]	Phase II RCT	NACT + HT vs. NACT in stage IIB–IIIA breast cancer	N = 200	Better tumour and axillary LN size reduction. Increased objective response. Higher 10-year OS rates (p = 0.009).
Lung Cancer
Mitsumori et al., 2007 [44]	Phase II RCT	HT + RT vs. RT alone in LA NSCLC	N = 80	No difference in response rates or OS. Improved PFS (1-year 29.0% vs. 67.5%).
Shen et al., 2011 [45]	Phase II RCT	CT + HT vs. CT alone in advanced NSCLC	N = 80	No change in response rates. Better QoL improvements (especially pain response) with HT.
Ou et al., 2020 [46]	Phase II RCT	IV VitC + meHT vs. BSC in advanced NSCLC	N = 97	Improved disease control rate. Prolonged PFS. Better OS (9.4 m vs. 5.6 m; p < 0.05). Better QoL outcomes.
Lee et al., 2013 [47]	Prospective comparative trial	CT + mEHT vs. CT alone in SCLC	N = 31	Improved survival (p < 0.02).